Patheon BV, a leading contract development and manufacturing organisation (CDMO), is headquartered in the United States and operates extensively across Europe and Asia. Founded in 1974, Patheon has established itself as a key player in the pharmaceutical and biotechnology industries, specialising in drug development, manufacturing, and delivery solutions. The company offers a comprehensive range of services, including formulation development, clinical trial manufacturing, and commercial production, distinguished by its commitment to quality and innovation. Patheon’s state-of-the-art facilities and advanced technologies enable it to meet the diverse needs of its clients, ensuring efficient and reliable product delivery. With a strong market position, Patheon BV has achieved notable milestones, including strategic partnerships and expansions that enhance its global footprint. Its dedication to excellence has solidified its reputation as a trusted partner for pharmaceutical companies seeking to bring life-saving therapies to market.
How does Patheon BV's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Patheon BV's score of 73 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Patheon BV, headquartered in the US, currently does not report specific carbon emissions data, as no figures are available. However, the company is part of a corporate family relationship with Thermo Fisher Scientific Inc., which cascades its climate commitments and performance metrics to Patheon BV. Thermo Fisher Scientific Inc. has established various climate initiatives, including Science Based Targets Initiative (SBTi) commitments and participation in the Carbon Disclosure Project (CDP). These initiatives aim to enhance sustainability and reduce carbon footprints across their operations. As a current subsidiary of Thermo Fisher Scientific Inc., Patheon BV aligns with these broader corporate sustainability goals, although specific reduction targets or achievements for Patheon BV itself have not been disclosed. The absence of direct emissions data highlights the need for ongoing transparency and commitment to climate action within the pharmaceutical manufacturing sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 321,190,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 486,151,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 |
Patheon BV's Scope 3 emissions, which decreased by 26% last year and decreased by approximately 37% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 58% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Patheon BV has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.